Document is current
Any future updates will be listed below
-
Authors
Cavalloni, Giuliana
Peraldo-Neia, Caterina
Massa, Annamaria
Bergamini, Carlo
Trentini, Alessandro
De Rosa, Giovanni
Daniele, Lorenzo
Ciccosanti, Fabiola
Cervellati, Carlo
Leone, Francesco
Aglietta, Massimo
- License Information
-
More Information
Article History
Received: 20 November 2020
Accepted: 9 July 2021
First Online: 28 July 2021
Declarations
:
: This study was approved by the institutional Ethics committee (FPO-IRCCS, Candiolo Cancer Institute, Candiolo, Torino).The study was carried out in accordance with the guidelines included the approved protocol (PROFILING protocol: “Prospective study for the determination of molecular profiles of patients affected by tumors resistant to target therapies.” Ethic code: 001-IRCC-00IIS-10, version 6.1, 23 June 2016).Informed consent was obtained from all subjects/patients included in this study. All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). Cell line used in the present study did not require ethics approval for their use.
: Not applicable.
: The authors declare that they have no competing interests
